Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

2.8K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.8K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

3.8K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
3.8K
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

3.3K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
3.3K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.7K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

687
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
687
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

1.1K
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Sublingual artery injury during dental implantation using a surgical navigation guide].

Stomatologiia·2023
Same author

[Antibiotic prophylaxis for infective endocarditis: current approaches].

Kardiologiia·2021
Same author

[Anaemia and iron deficiency in chronic heart failure patients].

Kardiologiia·2019
Same author

[The case of repeated syncopes in recurrent pulmonary embolism].

Kardiologiia·2018
Same author

RELATIONSHIP BETWEEN BLOOD ALDOSTERONE AND SOMATOMETRIC PARAMETERS IN PATIENTS WITH CHRONIC HEART FAILURE AND PRESERVED EJECTION FRACTION OF LEFT VENTRICLE.

Klinicheskaia meditsina·2017
Same author

[Infective endocarditis in the elderly: The current view of the problem].

Terapevticheskii arkhiv·2017

Related Experiment Video

Updated: Mar 6, 2026

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish
06:15

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish

Published on: August 16, 2024

886

[The Development of Pulmonary Damage When Receiving Amiodarone].

N T Vatutin1, A N Shevelyok1, A E Degtiarova1

  • 1Donetsk National Medical University named after M. Gorky, Donetsk, Ukraine.

Kardiologiia
|March 15, 2017
PubMed
Summary
This summary is machine-generated.

Amiodarone, an antiarrhythmic drug, can cause a dangerous side effect known as amiodarone-induced pulmonary toxicity. This report details a clinical case of this severe adverse reaction.

Keywords:
amiodaronedrug induced pulmonary toxicitylipid laden macrophagelung injuryside effects

More Related Videos

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.7K
A Chronic Cardiac Ischemia Model in Swine Using an Ameroid Constrictor
08:22

A Chronic Cardiac Ischemia Model in Swine Using an Ameroid Constrictor

Published on: October 9, 2017

11.2K

Related Experiment Videos

Last Updated: Mar 6, 2026

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish
06:15

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish

Published on: August 16, 2024

886
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.7K
A Chronic Cardiac Ischemia Model in Swine Using an Ameroid Constrictor
08:22

A Chronic Cardiac Ischemia Model in Swine Using an Ameroid Constrictor

Published on: October 9, 2017

11.2K

Area of Science:

  • Cardiology
  • Pulmonology
  • Clinical Pharmacology

Background:

  • Amiodarone is a widely prescribed antiarrhythmic medication used to treat various cardiac arrhythmias.
  • While effective, amiodarone is associated with a spectrum of serious adverse effects, including pulmonary toxicity.
  • Early recognition and management of amiodarone-induced pulmonary toxicity are crucial for patient outcomes.

Observation:

  • This report presents a detailed clinical case of amiodarone-induced pulmonary toxicity.
  • The case highlights the diagnostic challenges and clinical presentation of this severe side effect.
  • Observations focus on the patient's symptoms, diagnostic workup, and treatment course.

Findings:

  • Amiodarone-induced pulmonary toxicity represents a significant and potentially fatal complication of amiodarone therapy.
  • The findings underscore the importance of vigilant monitoring for respiratory symptoms in patients receiving amiodarone.
  • This case illustrates a specific manifestation of amiodarone's adverse effects on lung tissue.

Implications:

  • Clinicians should maintain a high index of suspicion for amiodarone-induced pulmonary toxicity in patients on this medication presenting with respiratory complaints.
  • Prompt diagnosis and cessation of amiodarone are critical to prevent irreversible lung damage.
  • Further research into predictive markers and preventative strategies for amiodarone pulmonary toxicity is warranted.